Articles by James Harding, MD
The panel ends with challenges and current limitations of biomarkers in HCC, emphasizing the need for more effective tools.
The panel highlights the lack of definitive data and the rationale behind using second-line TKIs or ICIs.
The panel explores how treatment goals in advanced HCC have evolved, in light of unpredictable long-term responders to IO.
The panel examines the role of len/pembro, weighing its clinical activity against the backdrop of a negative phase III trial.
The panel focuses on how they approach regimen selection amid new options like ipi/nivo, atezo/bev, and durva/treme.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.